Zobrazeno 1 - 10
of 32
pro vyhledávání: ''
Autor:
Xin Sun, Qing Luo, Li Liang, Wei Liu, Huaichuan Duan, Jianping Hu, Xinyu Liu, Gang Zhao, Yichen Hu, Hua Wan, Lianxin Peng, Ya Gan, Hubing Shi
Publikováno v:
Current Protein & Peptide Science. 21:1027-1039
Indoleamine 2, 3-dioxygenase 1 (IDO1) is the only rate-limiting enzyme outside the liver that catalyzes the oxidation and cracking of indole rings in the tryptophan along the kynurenine pathway (KP). The overactivation of IDO1 is closely related to t
Autor:
Veronika Anita Deák, Enno Klussmann
Publikováno v:
Current Drug Targets. 17:1147-1171
A-kinase anchoring proteins (AKAPs) control the localization of cAMP-dependent protein kinase A (PKA) by tethering PKA to distinct cellular compartments. Through additional direct proteinprotein interactions with PKA substrates and other signaling mo
Publikováno v:
Current Cancer Drug Targets. 16:136-146
Selective degradation of pathogenic proteins by small molecules in cells is a novel approach for development of therapeutic agents against various diseases, including cancer. We and others have developed a protein knockdown technology with a series o
Autor:
Chiharu Uchida, Masatoshi Kitagawa
Publikováno v:
Current Cancer Drug Targets. 16:157-174
In the ubiquitylation system, E3 ubiquitin ligases play a key role in determining substrate specificity and catalyzing the transfer of ubiquitin from E2 enzymes to the substrate. Growing evidence has shown that E3 ubiquitin ligases are involved in ca
Autor:
Kyoko Kitagawa, Masatoshi Kitagawa
Publikováno v:
Current Cancer Drug Targets. 16:119-129
The ubiquitin system controls protein stability and function. F-box proteins form SCF (SKP1-Cullin1-F-box protein)-type ubiquitin (E3) ligases to selectively target their substrates for degradation via the ubiquitin-proteasome pathway. Here, we revie
Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer
Autor:
Takahito Tanaka, Chihiro Sumita, Hidetoshi Hayashi, Yasumichi Inoue, Fumihiro Kawasaki, Daisuke Morishita, Yuka Itoh, Koichi Sato
Publikováno v:
Current Cancer Drug Targets. 16:110-118
Epithelial-mesenchymal transition (EMT) plays an important role in the development of tumor metastases by facilitating cell migration and invasion. One of the hallmarks of EMT is the diminished expression of E-cadherin and gain of mesenchymal traits,
Autor:
Caroline Barette, Renaud Prudent, Catherine Pillet, Laurence Lafanechère, Emilie Vassal-Stermann, Emmanuelle Soleilhac, Anne Martinez, Attilio Di Pietro, Gustavo Jabor Gozzi, Marie-Odile Fauvarque
Publikováno v:
Current Cancer Drug Targets
Current Cancer Drug Targets, Bentham Science Publishers, 2015, 15 (1), pp.2-13. ⟨10.2174/1568009615666141215154149⟩
Current Cancer Drug Targets, 2015, 15 (1), pp.2-13. ⟨10.2174/1568009615666141215154149⟩
Current Cancer Drug Targets, Bentham Science Publishers, 2015, 15 (1), pp.2-13. ⟨10.2174/1568009615666141215154149⟩
Current Cancer Drug Targets, 2015, 15 (1), pp.2-13. ⟨10.2174/1568009615666141215154149⟩
International audience; Microtubule drugs have been widely used in cancer chemotherapies. Although microtubules are subject to regulation by signal transduction mechanisms, their pharmacological modulation has so far relied on compounds that bind to
Autor:
Chi-Meng Tzeng, Run-Sheng Ruan, Qing Lin, Wen-Qing Huang, Zhongxian Lu, Xuan Zhuang, Liang-Liang Cai
Publikováno v:
Current Cancer Drug Targets. 14:567-588
Src homology 2 (SH2)-containing protein tyrosine phosphatase 2 (SHP2), encoded by the human PTPN11 gene, is a ubiquitously expressed protein tyrosine phosphatase (PTP) that consists of two tandem Src homology (SH2) domains (N-SH2 and C-SH2), a PTP ca
Publikováno v:
Current Cancer Drug Targets. 14:549-556
The Neuronally expressed developmentally downregulated 4 (NEDD4), functioning largely as an E3 ubiquitin ligase, has been demonstrated to play a critical role in the development and progression of human cancers. In this review, to understand the regu
Autor:
Eric J. Sundberg, Greg A. Snyder
Publikováno v:
Current Pharmaceutical Design. 20:1244-1258
The ability of a single protein fold to make multi-modal interactions with itself and others for transmitting biological signals across multiple receptor families is a recurring theme in signal transduction. The Toll/IL-1 receptor (TIR) domain repres